Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs. $2.5 billion in 2022, with just under 70% stemming from the US, according to a report from Bloomberg Intelligence.
Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.
Bora Pharmaceuticals is a pharmaceutical company that provides solutions for the development, manufacturing, and packaging of pharmaceutical products. In the large molecule space, it offers comprehensive services from the development of mammalian cell...
Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, will be presenting at the upcoming 2023 BIO International Convention in Boston.
Purolite, an Ecolab company based in Pennsylvania, is a leading manufacturer of healthcare, pharmaceutical and life science products. Its affinity and ion exchange resins are used in various purification processes in the manufacture of biologics.
Scarlet Therapeutics, a leader in red blood cell-based therapeutics, has raised seed funding from Science Creates Ventures and Meltwind to develop its platform and build a pipeline of novel therapies.
Neurimmune has announced that primary results of its phase 1 proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR cardiomyopathy, have been presented in Prague at Heart Failure 2023, a scientific congress of...
US biopharma Insmed has announced progress across its early-stage research programs at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.
Locate Bio, a UK-based orthobiologics company, has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft.
HexisLab, a UK biotech company, has secured a £490,000 funding grant from Innovate UK to develop a scale-up manufacturing process for its novel sustainable and green ingredients.
Sania Therapeutics, a new biotech company focused on developing genetic medicines for neural circuit dysfunction, has launched by unveiling its suite of proprietary patented platforms at the American Society of Gene & Cell Therapy (ASGCT) conference.
Lumen Bioscience has announced that the US Food and Drug Administration (FDA) has granted fast track designation for LMN-201, its biologic drug to treat and prevent C. difficile infection (CDI).
Waters Corporation has officially completed its acquisition of Wyatt Technology, a leading provider of light scattering and field-flow fractionation instruments, software, accessories, and services.
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting.
iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.
Mursla Bio will present its novel tissue-specific Extracellular Vesicle (EV) isolation technology NEXPLOR at the International Society for Extracellular Vesicles (ISEV) annual meeting.
TILT Biotherapeutics, a biotech company developing cancer immunotherapies, has announced that the first patient has been dosed in a phase 1 trial of the company’s oncolytic adenovirus TILT-123.
SiSaf has been granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (PRDD) by the US Food and Drug Administration (FDA) for its osteopetrosis treatment, SIS-101-ADO.
Acesion Pharma has announced positive data from pre-clinical studies with AP31969, developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence.
Data from the company’s lead fibrosis asset called RXC700 has highlighted multiple opportunities for patients with pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC).
UCB and Ariceum have announced a strategic research collaboration to identify and develop systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases.
Servier has received marketing approval from the European Commission (EC) for Tibsovo (ivosidenib tablets) to treat isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukaemia (AML) and IDH1-mutated cholangiocarcinoma.
Cellular Origins has partnered with ScaleReady, to automate portions of its cell and gene therapies (CGT) manufacturing workflow using a robotics system for sterile liquid transfer.
Fusion Pharmaceuticals, a clinical-stage oncology company, has announced the opening of its new state-of-the-art radiopharmaceutical manufacturing facility at Ontario-based McMaster University.
Hansa Biopharma and Genethon have entered a research and development collaboration to test imlifidase as a gene therapy treatment in patients with pre-existing neutralizing antibodies.
Memo Therapeutics, a biotech company developing therapeutic antibodies, has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to AntiBKV.
Vir Biotechnology has been awarded a new $10 million grant by the Bill & Melinda Gates Foundation to support its novel T cell vaccine development program for the prevention of HIV.
Mekonos, a biotech platform developing cell therapies, has announced a new research collaboration with bit.bio, a synthetic biology company providing human cells for research, drug discovery and cell therapy.
The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.
In first quarter 2023 financials, the company reported a drop in net revenue of close 10%, as the impact of Humira biosimilar entry onto the market begins to bite.
After decades of respiratory syncytial virus (RSV) vaccine research, a vaccine candidate for RSV developed by GSK, Arexvy, has become the first of its kind to be approved globally.
Protein drugs are notoriously difficult to deliver orally – but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.